Shockwave Medical, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000164254524000091 Filed on May 06, 2024

Income Statement

Concept	2024 Q2	2024 Q1

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.029B
YoY Change		146.9%
Cash & Equivalents		$281.7M
Short-Term Investments		$747.6M
Other Short-Term Assets		$10.46M
YoY Change		63.49%
Inventory		$111.2M
Prepaid Expenses
Receivables		$124.4M
Other Receivables		$0.00
Total Short-Term Assets		$1.275B
YoY Change		115.86%
LONG-TERM ASSETS
Property, Plant & Equipment		$78.69M
YoY Change		45.57%
Goodwill		$39.57M
YoY Change
Intangibles		$91.96M
YoY Change
Long-Term Investments		$2.356M
YoY Change		-12.38%
Other Assets		$9.001M
YoY Change		47.27%
Total Long-Term Assets		$368.4M
YoY Change		91.45%
TOTAL ASSETS
Total Short-Term Assets		$1.275B
Total Long-Term Assets		$368.4M
Total Assets		$1.644B
YoY Change		109.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$9.843M
YoY Change		-10.92%
Accrued Expenses		$78.84M
YoY Change		58.82%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$92.33M
YoY Change		-34.98%
LONG-TERM LIABILITIES
Long-Term Debt		$732.8M
YoY Change		2924.27%
Other Long-Term Liabilities		$7.659M
YoY Change		-83.47%
Total Long-Term Liabilities		$7.659M
YoY Change		-68.39%
TOTAL LIABILITIES
Total Short-Term Liabilities		$92.33M
Total Long-Term Liabilities		$7.659M
Total Liabilities		$892.0M
YoY Change		319.64%
SHAREHOLDERS EQUITY
Retained Earnings		$165.8M
YoY Change		7071.76%
Common Stock		$586.1M
YoY Change		3.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$751.8M
YoY Change
Total Liabilities & Shareholders Equity		$1.644B
YoY Change		109.86%

Cashflow Statement

Concept	2024 Q2	2024 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Shockwave Medical, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0494101
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5403 Betsy Ross Drive
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Santa Clara
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95054
CY2024Q1	dei	City Area Code CityAreaCode	510
CY2024Q1	dei	Trading Symbol TradingSymbol	SWAV
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37543542	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	281674000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	328422000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	747559000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	662132000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	114552000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	107587000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10462000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12567000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1275350000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1225260000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34919000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29707000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78693000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68923000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	2356000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1643000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	92857000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	39568000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	39568000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	111900000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	99169000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9001000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9436000	usd
CY2024Q1	us-gaap	Assets Assets	1643747000	usd
CY2023Q4	us-gaap	Assets Assets	1566563000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9843000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8868000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78838000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91696000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3653000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3641000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	92334000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	104205000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40336000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35103000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12273000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12273000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3609000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3609000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	218805000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	161066000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28207000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21066000	usd
CY2024Q1	dei	Security12b Title Security12bTitle	Shockwave Medical, Inc., common stock, par value $0.001 per share
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	124440000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	111215000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	91960000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	891990000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-109000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	165811000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	751757000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1643747000	usd
CY2024Q1	dei	Entity File Number EntityFileNumber	001-38829
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001642545
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	279-4262
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	732810000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	731863000	usd
CY2024Q1	swav	Long Term Income Tax Liability LongTermIncomeTaxLiability	2969000	usd
CY2023Q4	swav	Long Term Income Tax Liability LongTermIncomeTaxLiability	1526000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7659000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9307000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	897886000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	38000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	37000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	586017000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	557882000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	293000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	110465000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	668677000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1566563000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	190598000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	140000000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44466000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26971000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	74492000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	54011000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29233000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19204000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	148191000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	100186000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	42407000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	39814000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	713000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-823000	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	12318000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1740000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	2943000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	636000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2496000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	642000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	49999000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	40737000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5347000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1612000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	55346000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39125000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-402000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	505000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	5000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	54944000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	39625000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.48
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.44
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37284946	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36427263	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38472013	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37979448	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	668677000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	750000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4269000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23125000	usd
CY2024Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-8000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-402000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	55346000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	751757000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	511316000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	320000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	505000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	5000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3092000	usd
CY2023Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-3000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16337000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	39125000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	570687000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	55346000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	39125000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3109000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1708000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	713000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-823000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	22937000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	15967000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	887000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	748000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	9897000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	718000	usd
CY2024Q1	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	8000	usd
CY2023Q1	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	11000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-12557000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-547000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	947000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	33000	usd
CY2024Q1	swav	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-2268000	usd
CY2023Q1	swav	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	689000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1648000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9014000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13004000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3285000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7757000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2144000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1896000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-438000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	861000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	416000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4734000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-16135000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6661000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-854000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-846000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1443000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	35840000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	33962000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	400599000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	21130000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	324535000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	34500000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8389000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7188000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-84453000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6182000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	750000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	320000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4269000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3092000	usd
CY2024Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2023Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	80000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5011000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83409000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3175000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	792000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46777000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	124345000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	329826000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158302000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283049000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	282647000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	3870000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	424000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	4593000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	322000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6099000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7334000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6162000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1029200000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	281674000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	280932000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	1375000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1715000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	283049000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	282647000	usd
CY2024Q1	swav	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	882534000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	89000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	232000	usd
CY2024Q1	swav	Cash Equivalents And Short Term Investments Fair Value Disclosure CashEquivalentsAndShortTermInvestmentsFairValueDisclosure	882391000	usd
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	134832000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	747559000	usd
CY2024Q1	swav	Cash Equivalents And Short Term Investments Fair Value Disclosure CashEquivalentsAndShortTermInvestmentsFairValueDisclosure	882391000	usd
CY2023Q4	swav	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	814328000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	469000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000	usd
CY2023Q4	swav	Cash Equivalents And Short Term Investments Fair Value Disclosure CashEquivalentsAndShortTermInvestmentsFairValueDisclosure	814719000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	152587000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	662132000	usd
CY2023Q4	swav	Cash Equivalents And Short Term Investments Fair Value Disclosure CashEquivalentsAndShortTermInvestmentsFairValueDisclosure	814719000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	564100000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	45900000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	100000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	736694000	usd
CY2024Q1	swav	Available For Sale Securities Debt Maturities Within Greater Than One Year And Less Than Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinGreaterThanOneYearAndLessThanTwoYearsFairValue	60691000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	882391000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28715000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	25670000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	22604000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	16499000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	59896000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	65418000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	111215000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	107587000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	34076000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49706000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10972000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6269000	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	9532000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	9507000	usd
CY2024Q1	swav	Accrued Asset Purchases Current AccruedAssetPurchasesCurrent	9054000	usd
CY2023Q4	swav	Accrued Asset Purchases Current AccruedAssetPurchasesCurrent	7788000	usd
CY2024Q1	swav	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	7477000	usd
CY2023Q4	swav	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	8122000	usd
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3334000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3495000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4393000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6809000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78838000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91696000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1444000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1211000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	267000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	300000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	1711000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	1511000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1400000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4619000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6700000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6897000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7076000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7242000	usd
CY2024Q1	swav	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	23074000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	55608000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10320000	usd
CY2024Q1	swav	Lessee Operating Lease Lease Incentive LesseeOperatingLeaseLeaseIncentive	1299000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	43989000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3653000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40336000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22937000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15967000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	200000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	400000	usd
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2000430	shares
CY2019Q1	swav	Maximum Period Of Automatic Annual Increase In Common Stock Reserved For Issuance MaximumPeriodOfAutomaticAnnualIncreaseInCommonStockReservedForIssuance	P10Y
CY2019Q1	swav	Automatic Annual Increase In Common Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Preceding Fiscal Year End Date AutomaticAnnualIncreaseInCommonStockReservedForIssuanceAsPercentageOfCapitalStockOutstandingOnPrecedingFiscalYearEndDate	0.03
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4220428	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	880809000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5900
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	162653000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	182290000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4110
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	698519000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6360
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	167047000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	698519000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6360
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M12D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	167047000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	55346000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39125000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37284946	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36427263	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37284946	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36427263	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38472013	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37979448	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.48
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.44
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	405559	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100755	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	218805000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	161066000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	218805000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	161066000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	700000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-800000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5300000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1069
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.0396
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
swav-20240331_cal.xml	Edgar Link	unprocessable
0001642545-24-000091-index-headers.html	Edgar Link	pending
0001642545-24-000091-index.html	Edgar Link	pending
0001642545-24-000091.txt	Edgar Link	pending
0001642545-24-000091-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
swav-20240331.htm	Edgar Link	pending
swav-20240331.xsd	Edgar Link	pending
swav-ex31_1xq124.htm	Edgar Link	pending
swav-ex31_2xq124.htm	Edgar Link	pending
swav-ex32_1xq124.htm	Edgar Link	pending
swav-ex32_2xq124.htm	Edgar Link	pending
swav-20240331_def.xml	Edgar Link	unprocessable
swav-20240331_lab.xml	Edgar Link	unprocessable
swav-20240331_pre.xml	Edgar Link	unprocessable
swav-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Shockwave Medical, Inc.

2024 Q2 Form 10-Q Financial Statement

#000164254524000091 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission